Comparison of calculated body muscle mass and SARC‑F as methods of screening for sarcopenia in patients with chronic liver disease

Ichikawa,Tatsuki; Miyaaki,Hisamitsu; Miuma,Satoshi; Motoyoshi,Yasuhide; Yamashima,Mio; Yamamichi,Shinobu; Koike,Makiko; Nakano,Yusuke; Honda,Tetsurou; Yajima,Hiroyuki; Uehara,Ryouhei; Miyazaki,Osamu; Kuribayashi,Yasutaka; Kira,Keiji; Taura,Naota; Nakao,Kazuhiko

doi:10.3892/br.2021.1410

Comparison of calculated body muscle mass and SARC‑F as methods of screening for sarcopenia in patients with chronic liver disease

Authors:
- Tatsuki Ichikawa
- Hisamitsu Miyaaki
- Satoshi Miuma
- Yasuhide Motoyoshi
- Mio Yamashima
- Shinobu Yamamichi
- Makiko Koike
- Yusuke Nakano
- Tetsurou Honda
- Hiroyuki Yajima
- Ryouhei Uehara
- Osamu Miyazaki
- Yasutaka Kuribayashi
- Keiji Kira
- Naota Taura
- Kazuhiko Nakao
View Affiliations

Affiliations: Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850‑8555, Japan, Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852‑8501, Japan, Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850‑8555, Japan
Published online on: February 11, 2021 https://doi.org/10.3892/br.2021.1410
Article Number: 34
Copyright: © Ichikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A simple method is required to screen for sarcopenia in patients with chronic liver disease. In the present study, the value of the existing SARC‑F questionnaire as well as calculated body muscle mass (CBMM) approaches were assessed for screening of sarcopenia. A total of 482 patients with chronic liver disease underwent CBMM, grip strength (GS) and SARC‑F score assessments. Cross‑sectional computed tomography images of the third lumbar vertebrae were analyzed to determine the skeletal muscle (SM) mass in 303 patients. Cutoff CBMM values for sarcopenia were <27.903 in females and <39.731 in males. The cutoff SARC‑F score for sarcopenia was ≥4 points. Sarcopenia was diagnosed using the criteria described in the Japan Society of Hepatology. GS was moderately correlated with SARC‑F score (females, R=‑0.578; males, ‑0.453) and CBMM (females, R=0.497; males, 0.548). The SM index was moderately correlated with CBMM for both sexes (females, R=0.546; males, 0.612), but not with SARC‑F score in females (females, R=‑0.132; males, ‑0.246). The area under the curve (AUC) for CBMM against sarcopenia (0.85964) was significantly larger than that for SARC‑F score (0.72013) amongst males (P=0.03577) but not females. The AUCs for a modified SARC‑F questionnaire (encompassing the SARC‑F questionnaire, CBMM, sex and age; mSARC‑F) against sarcopenia were 0.864 in males and 0.78185 in females. As a screening method, SARC‑F is less useful than CBMM. However, the AUC for mSARC‑F is greater than SARC‑F and CBMM.

View Figures

View References

1	van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, Feshtali S, van Ooijen PMA, Polak WG, Porte RJ, et al: A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol. 68:707–714. 2018.PubMed/NCBI View Article : Google Scholar
2	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, et al: European Working Group on Sarcopenia in Older People: Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 39:412–423. 2010.PubMed/NCBI View Article : Google Scholar
3	IWG on Sarcopenia. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 12:249–256. 2009.
4	Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, et al: Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 15:95–101. 2014.PubMed/NCBI View Article : Google Scholar
5	Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, et al: Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2: Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 48:16–31. 2019.PubMed/NCBI View Article : Google Scholar
6	Malmstrom TK and Morley JE: Sarcopenia: the target population. J Frailty Aging. 2:55–56. 2013.PubMed/NCBI View Article : Google Scholar
7	Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al: Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 21:300–307.e2. 2020.PubMed/NCBI View Article : Google Scholar
8	Ida S, Kojima Y, Hamaoka S, Urawa N, Araki J, Kaneko R and Murata K: Validity of Japanese version of SARC-F questionnaire in patients with chronic liver disease. J Gastroenterol Hepatol. 34:947–953. 2019.PubMed/NCBI View Article : Google Scholar
9	Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Honda T, Yajima H, Uehara R, et al: Calculated body muscle mass as a useful screening marker for low skeleton muscle mass and sarcopenia in chronic liver disease. Hepatol Res. 50:704–714. 2020.PubMed/NCBI View Article : Google Scholar
10	Kim SW, Jung HW, Kim CH, Kim KI, Chin HJ and Lee H: A new equation to estimate muscle mass from creatinine and cystatin C. PLoS One. 11(e0148495)2016.PubMed/NCBI View Article : Google Scholar
11	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K and Nishiguchi S: Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 46:951–963. 2016.PubMed/NCBI View Article : Google Scholar
12	Hiraoka A, Izumoto H, Ueki H, Yoshino T, Aibiki T, Okudaira T, Yamago H, Suga Y, Iwasaki R, Tomida H, et al: Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test. J Cachexia Sarcopenia Muscle. 10:347–354. 2019.PubMed/NCBI View Article : Google Scholar
13	Hirota K, Kawaguchi T, Koya S, Nagamatsu A, Tomita M, Hashida R, Nakano D, Niizeki T, Matsuse H, Shiba N, et al: Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. Hepatol Res. 50:330–341. 2020.PubMed/NCBI View Article : Google Scholar
14	Child CG and Turcotte JG: Surgery and portal hypertension. Major Probl Clin Surg. 1:1–85. 1964.PubMed/NCBI
15	Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, et al: Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J Clin Oncol. 33:550–558. 2015.PubMed/NCBI View Article : Google Scholar
16	Kamath PS, Wiesner RH, Malinchoc M, Kremer W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER and Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology. 33:464–470. 2001.PubMed/NCBI View Article : Google Scholar
17	Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H and Pol S: FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 46:32–36. 2007.PubMed/NCBI View Article : Google Scholar
18	Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A: Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53:982–992. 2009.PubMed/NCBI View Article : Google Scholar
19	Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Takahashi Y, Honda T, Yajima H, et al: Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep. 12:89–98. 2020.PubMed/NCBI View Article : Google Scholar
20	Kashani KB, Frazee EN, Kukrálová L, Sarvottam K, Herasevich V, Young PM, Kashyap R and Lieske JC: Evaluating muscle mass by using markers of kidney function: development of the sarcopenia index. Crit Care Med. 45:e23–e29. 2017.PubMed/NCBI View Article : Google Scholar
21	Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami T, et al: Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 63:131–140. 2015.PubMed/NCBI View Article : Google Scholar
22	Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK and Gonzalez MC: Grupo de Estudos em Composição Corporal e Nutrição (COCONUT): Enhancing SARC-F: Improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc. 17:1136–1141. 2016.PubMed/NCBI View Article : Google Scholar
23	Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, Wang Y, Li Y, Han Z, Zhang D, et al: Screening sarcopenia in community-dwelling older adults: SARC-F vs SARC-F combined with calf circumference (SARC-CalF). J Am Med Dir Assoc. 19:277.e1–277.e8. 2018.PubMed/NCBI View Article : Google Scholar
24	Ida S, Murata K, Nakadachi D, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R and Takahashi H: Development of a Japanese version of the SARC-F for diabetic patients: An examination of reliability and validity. Aging Clin Exp Res. 29:935–942. 2017.PubMed/NCBI View Article : Google Scholar : Erratum in: Aging Clin Exp Res 32: 2113, 2020.
25	Hiraoka A, Nagamatsu K, Izumoto H, Yoshino T, Adachi T, Tsuruta M, Aibiki T, Okudaira T, Yamago H, Suga Y, et al: SARC-F combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatol Res. 50:502–511. 2020.PubMed/NCBI View Article : Google Scholar
26	Kera T, Kawai H, Hirano H, Kojima M, Watanabe Y, Motokawa K, Fujiwara Y, Osuka Y, Kojima N, Kim H, et al: Limitations of SARC-F in the diagnosis of sarcopenia in community-dwelling older adults. Arch Gerontol Geriatr. 87(103959)2020.PubMed/NCBI View Article : Google Scholar
27	Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L and Morley JE: SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 7:28–36. 2016.PubMed/NCBI View Article : Google Scholar
28	Yang M, Jiang J, Zeng Y and Tang H: Sarcopenia for predicting mortality among elderly nursing home residents: SARC-F versus SARC-CalF. Medicine (Baltimore). 98(e14546)2019.PubMed/NCBI View Article : Google Scholar
29	Papadopoulou SK: Sarcopenia: a contemporary health problem among older adult populations. Nutrients. 12(1293)2020.PubMed/NCBI View Article : Google Scholar